Clinical Virtues Of Carotid Stenting Prior To CREST Finale Debated At ACC
This article was originally published in The Gray Sheet
Executive Summary
Carotid stenting should be the standard of care for symptomatic and asymptomatic patients prior to completion of the Carotid Revascularization Endarterectomy Stenting Trial (CREST), Gary Roubin, MD, New York University School of Medicine said.
You may also be interested in...
PercuSurge, MedNova, AngioGuard Battle For Inclusion In CREST Study
PercuSurge, AngioGuard and MedNova, three of the frontrunners in the race to have their distal protection devices used in the upcoming Carotid Revascularization Endarterectomy Stenting Trial (CREST), exhibited their wares at the Jan. 22-26 International Symposium on Endovascular Therapy (ISET) in Miami Beach.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.